Finance entity
markets is the sole category represented across all 1 tracked stories. GSBR-1290 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window.
Last mentioned: Mar 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. GSBR-1290 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window. We currently track 1 Finance story that mention B Group, Inc., all published on March 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 109 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering B Group, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Structure Therapeutics (GPCR) has seen its shares decline 28% in early 2026, even as B Group, Inc. revealed a new $6.26 million position in the clinical-stage biotech. The company remains a key contender in the competitive oral GLP-1 market with its lead candidate GSBR-1290 showing strong mid-stage clinical results.
B Group, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
